ArticleBMC cancer2025
Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Histone succinylation directly inhibits Jumonji domain demethylases and stabilizes repressive chromatin states.bioRxiv : the preprint server for biology · 2026Article
- SLC25A39 Upregulation Is Associated with DNA Methylation, Immune Cell Infiltration, and Poor Prognosis in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Article
- Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a common malignant tumor worldwide, with complex pathogenesis and poor clinical prognosis. It was shown that hepatocyte nuclear factor 1β (HNF1B) is strongly expressed in hepatocyte and involved in liver development. Relevant studies have shown that HNF1B can be used as a marker for the identification of hepatocellular cholangiocarcinoma. However, regarding the mechanism by which HNF1B regulates the behavior of cancer cells to influence the development, malignancy and metastasis ability of HCC, is poorly understood at present.
methodsIn this study, the proliferation, migration, invasion, and apoptosis of liver cancer cells was investigated by modulating the expression of HNF1B in HCC cells. Furthermore, bioinformatics analysis: including differential gene and survival analysis, clinical relevance, GO/KEGG enrichment, immune cell infiltration, gene pathway prediction and PPI network analysis were applied to explore the mechanism of HNF1B to influence the development, malignancy and metastasis of HCC.
resultsOur results indicated that over-expression of HNF1B promoted the proliferation (*P < 0.05), migration (***P < 0.001) and invasive (**P < 0.01) ability of HCC cells, while significantly inhibited apoptosis. Importantly, overexpression of HNF1B may be associated with the transformation process from hepatocellular carcinoma (HCC) to intrahepatic cholangiocarcinoma (ICC) (****P < 0.0001). Bioinformatics analysis showed that HNF1B increased tumor cell heterogeneity by remodeling in the tumor microenvironment including immune cell infiltration, cell adhesion, and extracellular matrix. Moreover, HNF1B regulates the transformation of HCC to ICC through Notch, Hippo and neuroactive ligand-receptor interaction signaling pathways.
conclusionsOur study elucidated the functional roles of HNF1B on regulating the biological behavior of HCC cells, suggesting that HNF1B could be an important molecular marker of HCC. This finding provides a potential molecular target for the diagnosis and prognosis of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.